Table 1.

Correlation of tumor MTSS1 mRNA expression level with clinicopathological parameters of HCC patients

Clinicopathological parameters	Number	MTSS1/GAPDH mRNA (n)		P
		MTSS1-low group	MTSS1-high group
		(≤0.18, n = 17)	(>0.18, n = 20)
Age	37			0.900
≤ 52 y	20	9	11
> 52 y	17	8	9
Sex	37			0.588
Female	8	3	5
Male	29	14	15
Cirrhosis	37			0.855
Yes	30	14	16
No	7	3	4
Tumor number	37			0.035*
Multiple	20	6	14
Single	17	11	6
Satellite	36a			0.019*
Yes	15	3	12
No	21	13	8
Tumor size, cm	37			0.212
≤ 5	7	5	2
> 5	30	12	18
Encapsulation	37			0.008**
Complete	15	11	4
Incomplete or none	22	6	16
Vascular invasion	36a			0.042*
Yes	21	6	15
No	15	11	4
TNM stage	37			0.033*
Early stage (II)	7	6	1
Advanced stage (III-IVA)	30	11	19
AFP level, ng/mL	37			0.036*
≤ 20	11	2	9
> 20	26	15	11
γ-Glutamyl transferase, units/L	37			0.134
≤ 54	19	11	8
> 54	18	6	12
Adjuvant TACE	37			0.815
Yes	16	7	9
No	21	10	11

NOTE: HCC hepatocellular carcinoma, TACE transcatheter arterial chemoembolization

Significant difference: * < 0.05, ** < 0.01

^aNumber less than 37 due to missing data